The Role of Gut Microbiome in Irritable Bowel Syndrome: Implications for Clinical Therapeutics
Biomolecules · 2024
DOI: 10.3390/biom14121643 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biomolecules, 2024. Verfasst von Yucui Zhao und 7 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Pharmacology of Traditional Chinese Medical Formulae, Ministry of Education, Tianjin University of Traditional Chinese Medicine, Ti…. Hauptthemen laut MEDLINE: Irritable Bowel Syndrome, Gastrointestinal Microbiome, Brain-Gut Axis. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 242 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Xiumei Gao, National Natural Science Foundation of China, National Nature Key Research and Development.
Abstract (Originalsprache)
Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder (FGID) characterized by chronic or recurrent gastrointestinal symptoms without organic changes, and it is also a common disorder of gut–brain interaction (DGBIs).. The symptoms of IBS not only affect the quality of life for individual patients but also place a significant burden on global healthcare systems. The lack of established and universally applicable biomarkers for IBS, along with the substantial variability in symptoms and progression, presents challenges in developing effective clinical treatments. In recent years, preclinical and clinical studies have linked the pathogenesis of IBS to alterations in the composition and function of the intestinal microbiota. Within the complex microbial community of the gut, intricate metabolic and spatial interactions occur among its members and between microbes and their hosts. Amid the multifaceted pathophysiology of IBS, the role of intestinal microenvironment factors in symptom development has become more apparent. This review aims to delve into the changes in the composition and structure of the gut microbiome in individuals with IBS. It explores how diet-mediated alterations in intestinal microbes and their byproducts play a role in regulating the pathogenesis of IBS by influencing the “brain-gut” axis, intestinal barrier function, immune responses, and more. By doing so, this review seeks to lay a theoretical foundation for advancing the development of clinical therapeutics for IBS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Key Laboratory of Pharmacology of Traditional Chinese Medical Formulae, Ministry of Education, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China.
- School of Chinese Materia Medica, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China.
- State Key Laboratory of Component-Based Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China.
Förderung
- Xiumei Gao
- National Natural Science Foundation of China
- National Nature Key Research and Development
Zitieren
APA
Zhao, Y., Zhu, S., Dong, Y., Xie, T., Chai, Z., Gao, X., Dai, Y., & Wang, X. (2024). The Role of Gut Microbiome in Irritable Bowel Syndrome: Implications for Clinical Therapeutics. Biomolecules. https://doi.org/10.3390/biom14121643
Vancouver
Zhao Y, Zhu S, Dong Y, Xie T, Chai Z, Gao X, et al. The Role of Gut Microbiome in Irritable Bowel Syndrome: Implications for Clinical Therapeutics. Biomolecules. 2024. doi:10.3390/biom14121643
BibTeX
@article{Zhao2024,
author = {Zhao, Yucui and Zhu, Shixiao and Dong, Yingling and Xie, Tian and Chai, Zhiqiang and Gao, Xiumei and Dai, Yongna and Wang, Xiaoying},
title = {The Role of Gut Microbiome in Irritable Bowel Syndrome: Implications for Clinical Therapeutics},
journal = {Biomolecules},
year = {2024},
doi = {10.3390/biom14121643}
}
EUVIMED